PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund
Biotechnology September 21, 2021
Ryan Allway September 21st, 2021 Psychedelics TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Company has been included to the North American Psychedelics Index, (the “Index”), which is... Read more
Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent Portfolio of Breakthrough Advanced Drug Delivery Technologies
September 21, 2021
Ryan Allway September 21st, 2021 Psychedelics Mycrodose Therapeutics successfully closes oversubscribed seven-figure financing round. Financing was funded by multiple high profile institutional investors, VCs, and Psychedelic Funds, including; The Conscious Fund, Negev Capital, Ambria Capital, K2 & Associates, Empath Ventures, Supernode, Receptor Fund, and many high profiles Silicon Valley... Read more
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
September 21, 2021
Ryan Allway September 21st, 2021 Psychedelics TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental... Read more
Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States
September 20, 2021
Ryan Allway September 20th, 2021 Psychedelics Retail Footprint to Include 12 Open Locations, with 15 Additional Clinics in Development, Ensures Accessibility to Millions with Affordable Treatments and Insurance Coverage National Presence Will Bring Psychedelic Wellness Treatment to the Masses VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ – Delic Holdings Corp (“Delic” or the “Company“)... Read more
Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
September 20, 2021
Ryan Allway September 20th, 2021 Psychedelics VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to file a pre-IND (Investigational New Drug) meeting... Read more
Enveric Biosciences Announces Closing of MagicMed Industries Acquisition
September 17, 2021
Ryan Allway September 17th, 2021 Psychedelics, Top News Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress NAPLES, Fla., Sept. 17, 2021 /PRNewswire/ — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer... Read more
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
September 14, 2021
Ryan Allway September 14th, 2021 Psychedelics NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) — Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to evaluate the safety and efficacy of... Read more
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
September 14, 2021
The nomination of Dr. Reznik is part of the company’s strategy to develop new psychedelic inspired medicines and therapies to address several mental health related conditions. The announcement follows the company’s recent launching of a Psilocybin and Psilocin Research Program taking place under license by Israeli Ministry of Health.... Read more
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
September 10, 2021
Ryan Allway September 10th, 2021 Psychedelics The investment provides CaaMTech with capital to advance compounds from its library into clinical trials ISSAQUAH, Wash., Sept. 08, 2021 (GLOBE NEWSWIRE) — CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing round,... Read more
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
September 10, 2021
Ryan Allway September 10th, 2021 Psychedelics BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect’s... Read more
